Compounds > pimozide
Page last updated: 2024-08-22

pimozide and ER-Negative PR-Negative HER2-Negative Breast Cancer

pimozide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Dees, S; Jasmin, JF; Mercier, I; Pontiggia, L1

Other Studies

1 other study(ies) available for pimozide and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
    Cancer biology & therapy, 2020, 06-02, Volume: 21, Issue:6

    Topics: Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Dopamine Antagonists; Female; Humans; Phosphorylation; Pimozide; STAT3 Transcription Factor; Triple Negative Breast Neoplasms; Tumor Cells, Cultured

2020